Regional and Practice Variation in Adherence to Guideline Recommendations for Secondary and Primary Prevention Among Outpatients with Atherothrombosis or Risk Factors in the US: A Report From the REACH Registry Amit Kumar, Gregg C. Fonarow, Kim A. Eagle, Alan T. Hirsch, Robert M. Califf, Mark J. Alberts, William E. Boden, P. Gabriel Steg, Mingyuan Shao, Deepak L. Bhatt, Christopher P. Cannon, on behalf of the REACH Registry Investigators
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Regional and Practice Variation in Adherence to Guideline Recommendations
for Secondary and Primary Prevention Among Outpatients with Atherothrombosis or Risk Factors in the US: A Report From
the REACH Registry
Amit Kumar, Gregg C. Fonarow, Kim A. Eagle, Alan T. Hirsch, Robert M. Califf, Mark J. Alberts, William E. Boden, P. Gabriel
Steg, Mingyuan Shao, Deepak L. Bhatt, Christopher P. Cannon, on behalf of the REACH Registry Investigators
Global REACH Registry: Study Design
Primary Objective:To explore the impact of both classic and new risk factors on the prevalence of cardiovascular (CV)
ischemic events among patients with, or at high risk for, atherothrombotic disease, on an
international basis
Global REACH Registry Objectives
Additional Aims:Assess use of risk management strategies and 1-, 2-,
3- and 4-year outcomes in a broad outpatient population encompassing various geographic regions
and physician specialties
1. Ohman EM et al, on behalf of the REACH Registry Investigators. Am Heart J 2006;151(4):786.e1-10.
Must include:
Signedwritten
informedconsent
Patients aged≥45 years
At least of four criteria1
1. Documented cerebrovascular diseaseIschemic stroke or TIA
• Anticipated difficulty in patient returning for follow-up visit
• Patient is currently hospitalized
• Patient is currently participating in a clinical trial
1. Bhatt DL et al, on behalf of the REACH Registry Investigators. JAMA 2006;295(2):180-189.
*Timelines are for worldwide participation; local timelines will be shorter
Global REACH Registry Timeline
Baseline Follow-up at 12 3 months
Follow-up at 24 3 months
Follow-up at 33 3 months
Follow-up at 45 3 months
Timing* Dec 2003 to June 2004
From baseline time
Last follow-up March 2006
June 2006 to June 2007
June 2007 to June 2008
Required Data
Subject Data Form:
Section 1
Subject Data Form: Section 2
(progression since baseline)
Subject Data Form: Section
3(progression
since lastfollow-up)
Subject Data Form: Section
4(progression
since lastfollow-up)
Subject Data Form: Section
5(progression
since lastfollow-up)
Patient details,
history and clinical
examinationRegular
medicationsEmployment
status
Clinical outcomesVascular interventionsRegular medicationsEmployment status
Participating physicians
Pre-defined at start of Registry
Based on local practice population• General practitioners, specialists
Mainly office-based, some hospital representation
Representative of:• Local environment• Country geography
Global Physician Selection
How were they selected?
What is their profile?
1. Ohman EM et al, on behalf of the REACH Registry Investigators. Am Heart J 2006;151(4):786.e1-10.
Main Specialty Breakdown of US Practitioner Involvement (n=1,599)
GP or Internist
Cardiologist
Endocrinologist, Neurologist, Vascular Surgeon, Angiologist, Other
1. Eagle KA et al, on behalf of the REACH Registry Investigators. Crit Pathw Cardiol 2009;8(2):91-97.
86.8%9.7%3.5%
Patients
Recruitment at each site
Maximum 20 per site
Within overall Registry timelines
Patient inclusion criteria• Documented atherothrombotic disease, or with ≥3 atherothrombotic risk factors
Real-life setting
Global Patient Selection: Patients Fitting Inclusion Criteria
How were they selected?
What is their profile?
1. Ohman EM et al, on behalf of the REACH Registry Investigators. Am Heart J 2006;151(4):786.e1-10.
REACH Registry:Adherence to Primary and Secondary
Prevention Guidelines in the US
Background and Objectives
Proven risk-reducing therapies for patients with or at risk for atherothrombotic events include antihypertensive, antiplatelet, antidiabetic, and lipid-lowering agents
Hospital-based studies have shown that better adherence to guideline-recommended risk-reducing therapies improves clinical outcomes
This analysis of the US cohort of the REACH Registry was undertaken to analyze the use of risk-reducing therapies for both primary and secondary atherothrombosis prevention, stratified by US Census Region and physician specialty
1. Kumar A et al, on behalf of the REACH Registry Investigators. Crit Pathw Cardiol 2009;8(3).
Patient Characteristics at Baseline – Stratified by US Census Region
1. Kumar A et al, on behalf of the REACH Registry Investigators. Crit Pathw Cardiol 2009;8(3).
Total(N = 25,686)
Northeast(n = 4775)
Midwest(n = 6267)
South(n = 9865)
West(n = 4507)
Symptomatic, % 74.2 72.5 76.4 74.5 72.5
Asymptomatic, % 25.8 27.5 23.6 25.5 27.5
Men, % 57.0 57.9 56.0 55.7 60.3
≥65 years of age, % 69.1 71.4 69.5 66.0 72.4
Caucasian, % 80.2 83.8 87.2 76.6 74.4
African American, % 10.8 9.8 9.6 14.8 4.8
Hispanic, % 5.5 3.3 1.6 6.2 11.7
Asian, % 2.8 2.6 1.3 1.7 8.0
Diabetes, % 51.7 49.6 50.8 52.5 53.2
Hypertension, % 87.5 87.6 87.9 88.0 85.9
Hypercholesterolemia, % 82.6 85.1 82.6 81.4 82.6
Obesity, % 42.1 43.4 45.3 42.1 36.9
Overweight, % 35.8 34.4 35.5 36.0 36.7
Former smoker, % 43.1 41.5 43.4 42.5 45.3
Current smoker, % 14.4 13.5 14.5 15.8 11.8
US Patient Characteristics at Baseline – Stratified by Physician Specialty
1. Kumar A et al, on behalf of the REACH Registry Investigators. Crit Pathw Cardiol 2009;8(3).
Antihypertensive Medication Use at Baseline Among US Patients with Diagnosed Hypertension or Elevated BP at Enrollment – Stratified by Physician Specialty
1. Kumar A et al, on behalf of the REACH Registry Investigators. Crit Pathw Cardiol 2009;8(3).